VEGF, Flt‑1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis

Zygoń,Justyna; Szajewski,Mariusz; Kruszewski,Wiesław  Janusz; Rzepko,Robert

doi:10.3892/mco.2016.1121

VEGF, Flt‑1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis

Authors:
- Justyna Zygoń
- Mariusz Szajewski
- Wiesław Janusz Kruszewski
- Robert Rzepko
View Affiliations

Affiliations: Department of General Surgery, Kościerzyna Hospital Ltd., Kościerzyna 83‑400, Poland, Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, Gdynia 81‑519, Poland, Department of Pathology, Prabuty Hospital Ltd., Prabuty 82‑550, Poland
Published online on: December 30, 2016 https://doi.org/10.3892/mco.2016.1121
Pages: 243-248

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis in the primary tumor is known to be necessary for tumor progression in adenocarcinomas of the colon. However, whether angiogenesis in the primary tumors of patients with colorectal cancer affects their prognosis has yet to be fully elucidated. The aim of the present study was to assess the association between selected pathoclinical parameters and overall survival of resectable colorectal cancer patients with the expression of angiogenesis‑promoting factors, including vascular endothelial growth factor (VEGF) and Fms‑like tyrosine kinase receptor (Flt‑1), and microvessel density (MVD) in the primary tumor. VEGF and Flt‑1 expression were assessed, as well as MVD (with anti‑CD34) by immunohistochemistry in 139 archived primary colorectal cancer tissue samples. These results were compared with the overall survival of the patients and potential prognostic pathoclinical parameters. A higher MVD in the tumors expressing Flt‑1 (P=0.04) was identified. However, there was no correlation between the pathoclinical parameters of colon cancer and Flt‑1 expression, VEGF expression, or MVD in the tumor. Furthermore, the intensity of VEGF expression, Flt‑1 expression and tumor MVD did not correlate with the overall survival of the patients. Therefore, although increased expression of VEGF and Flt‑1 was correlated with an increased expression of MVD in the primary tumors of resectable colorectal cancer patients, these factors were not correlated with prognostic pathoclinical factors and overall survival.

View Figures

View References

1	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
2	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI
3	Shinkaruk S, Bayle M, Laïn G and Déléris G: Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents. 3:95–117. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hofstaetter JG, Saad FA, Samuel RE, Wunderlich L, Choi YH and Glimcher MJ: Differential expression of VEGF isoforms and receptors in knee joint menisci under systemic hypoxia. Biochem Biophys Res Commun. 324:667–672. 2004. View Article : Google Scholar : PubMed/NCBI
6	Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 26:25–35. 2001. View Article : Google Scholar : PubMed/NCBI
7	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar : PubMed/NCBI
8	Rmali K, Puntis M and Jiang W: Tumour-associated angiogenesis in human colorectal cancer. Colorectal Dis. 9:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
9	Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B and Wu Y: Vascular endothelial growth factor receptor-1 in human cancer: Concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer. 116:(Suppl 4). S1027–S1032. 2010. View Article : Google Scholar
10	Shibuya M and Claesson-Welsh L: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 312:549–560. 2006. View Article : Google Scholar : PubMed/NCBI
11	Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S and Hicklin DJ: The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer. 119:1519–1529. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, Hicklin DJ, Ellis LM and Gallick GE: Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer. 94:1710–1717. 2006.PubMed/NCBI
13	Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438:820–827. 2005. View Article : Google Scholar : PubMed/NCBI
14	Kaplan RN, Rafii S and Lyden D: Preparing the ‘soil’: The premetastatic niche. Cancer Res. 66:11089–11093. 2006. View Article : Google Scholar : PubMed/NCBI
15	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Handbook. 7th. Springer; New York: 2010
16	Hamilton SR and Aaltonen LA: Pathology and genetics of tumours of the digestive system. IARC Press; Lyon: 2000
17	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Eng J Med. 324:1–8. 1991. View Article : Google Scholar
18	Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III: Eastern Cooperative Oncology Group Study E3200: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI
19	Duff SE, Jeziorska M, Kumar S, Haboubi N, Sherlocks D, O'Dwyer ST and Jayson GC: Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis. 9:793–800. 2007. View Article : Google Scholar : PubMed/NCBI
20	Teranishi N, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Seya T, Shinji S and Tajiri T: Identification of neovasculature using nestin in colorectal cancer. Int J Oncol. 30:593–603. 2007.PubMed/NCBI
21	Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G and Tahara E: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res. 4:2195–2200. 1998.PubMed/NCBI
22	Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K and Aikou T: Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer. Ann Surg Oncol. 5:585–589. 1998. View Article : Google Scholar : PubMed/NCBI
23	Isozaki H, Okajima K, Kawashima Y, Yamada S, Nakata E, Nishimura J and Ichinona T: Prognostic value of the number of metastatic lymph nodes in gastric cancer with radical surgery. J Surg Oncol. 53:247–251. 1993. View Article : Google Scholar : PubMed/NCBI
24	Gallego M Galindo, Fernández Acenero MJ, Ortega J Sanz and Aljama A: Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer. 36:55–60. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K and Chayama K: Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 64:61–73. 2003. View Article : Google Scholar : PubMed/NCBI
26	Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS and Hsu HC: Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg. 91:355–361. 2004. View Article : Google Scholar : PubMed/NCBI
27	Zheng S, Han MY, Xiao ZX, Peng JP and Dong Q: Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol. 9:1227–1230. 2003. View Article : Google Scholar : PubMed/NCBI
28	White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J and Murray JC: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 62:1669–1675. 2002.PubMed/NCBI
29	Lindmark G, Gerdin B, Sundberg C, Pahlman L, Bergström R and Glimelius B: Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol. 14:461–466. 1996.PubMed/NCBI
30	Vermeulen P, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY: Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation. Eur J Cancer. 32:2474–2484. 1996. View Article : Google Scholar
31	Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 147:9–19. 1995.PubMed/NCBI
32	Pusztaszeri MP, Seelentag W and Bosman FT: Immunohistochemical expression of endothelial markers CD31, CD34, Von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 54:385–395. 2006. View Article : Google Scholar : PubMed/NCBI
33	Duff SE, Li C, Garland JM and Kumar S: CD105 is important for angiogenesis: Evidence and potential applications. FASEB J. 17:984–992. 2003. View Article : Google Scholar : PubMed/NCBI
34	Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL and Perret GY: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 94:1823–1832. 2006. View Article : Google Scholar : PubMed/NCBI
35	Tanigawa N, Amaya H, Matsumura M and Shimomatsuya T: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 15:826–832. 1997.PubMed/NCBI
36	Custodio A, Barriuso J, de Castro J, Martínez-Marín V, Moreno V, Rodríguez-Salas N and Feliu J: Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives. Cancer Treat Rev. 39:908–924. 2013. View Article : Google Scholar : PubMed/NCBI
37	Kosaka Y, Mimori K, Fukagawa T, Ishikawa K, Etoh T, Katai H, Sano T, Watanabe M, Sasako M and Mori M: Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-1 overexpression in peripheral blood. Br J Cancer. 96:1723–1728. 2007. View Article : Google Scholar : PubMed/NCBI
38	Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964–3968. 1995.PubMed/NCBI
39	Okita NT, Yamada Y, Takahari D, Hirashima Y, Matsubara J, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H and Shimoda T: Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol. 39:595–600. 2009. View Article : Google Scholar : PubMed/NCBI
40	Ning Y, Lurje G, Danenberg K, Cooc J, Yang D, Pohl A, Zhang W and Lenz H: VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer. J Clin Oncol. 27:40402009.